Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Conn PJ, Christopoulos A, Lindsley CW
Nat Rev Drug Discov. 2009 8 (1): 41-54

PMID: 19116626 · PMCID: PMC2907734 · DOI:10.1038/nrd2760

Despite G-protein-coupled receptors (GPCRs) being among the most fruitful targets for marketed drugs, intense discovery efforts for several GPCR subtypes have failed to deliver selective drug candidates. Historically, drug discovery programmes for GPCR ligands have been dominated by efforts to develop agonists and antagonists that act at orthosteric sites for endogenous ligands. However, in recent years, there have been tremendous advances in the discovery of novel ligands for GPCRs that act at allosteric sites to regulate receptor function. These compounds provide high selectivity, novel modes of efficacy and may lead to novel therapeutic agents for the treatment of multiple psychiatric and neurological human disorders.

MeSH Terms (8)

Allosteric Regulation Animals Central Nervous System Diseases Drug Design Drug Evaluation, Preclinical Humans Ligands Receptors, G-Protein-Coupled

Connections (3)

This publication is referenced by other Labnodes entities: